Publication date: November 17, 2026
For almost two decades, European universities measured research impact in patents, licences and spin-offs. The EU has since moved the goalposts. Under Council Recommendation (EU) 2022/2415 and four codes of practice adopted in 2023-2024, the benchmark is now “knowledge valorisation”: turning all intellectual assets, from data and know-how to standards and citizen science, into economic and societal value. In 2025-2026 the policy began to harden into binding law, with the European Innovation Act proposed in September 2026, a European Research Area (ERA) Act in the pipeline and the next Framework Programme (FP10, 2028-2034) under negotiation. Polish universities, still operating largely on a 2008-era technology transfer model under the Law on Higher Education and Science, have a narrowing window to adapt.
More
Publication date: November 16, 2026
Online sales of semaglutide and other active substances in Poland – regulatory exposure for sellers, marketplaces, advertisers and logistics operators
Vials of semaglutide and other peptides are sold online in Poland as “research chemicals” and delivered to parcel lockers without a prescription. The label is meant to keep the product outside pharmaceutical law. It does not: under EU and Polish law the classification of a product follows its presentation and its effect, not the seller’s disclaimer. For businesses, the practical question is therefore not whether this trade is legal, but who in the chain – seller, marketplace, advertiser, influencer, payment or logistics provider – carries the criminal, administrative and civil risk, and how quickly Polish enforcement tools are catching up.
More
Publication date: November 12, 2026
A blockchain is a public ledger, yet the proceeds of crypto fraud still disappear every day. Using the AdBlast pyramid scheme, which according to press reports harmed up to 90,000 people and caused losses of around USD 32 million, we trace how investor money is moved from a “private wallet” to cash withdrawn at an ATM. We then look at the criminal, fiscal and regulatory tools available in Poland as of November 2026, a moment when MiCA’s transitional period has expired but Poland still has no national crypto-asset supervisor, and at what this means for victims seeking to recover their funds.
More
Publication date: October 05, 2026
Poland’s Ministry of Health wants to place medicines with different active substances in a single reimbursement limit group where they work in a similar way, and to reward hospitals for choosing the cheapest therapy available. The change is meant to bring prices down and free up funds for innovative treatment, but clinicians warn that cost equivalence is not the same as clinical equivalence. We examine how the proposed baskets of equivalent therapeutic technologies could affect physicians’ autonomy, patients’ rights and competition in the pharmaceutical market, and what safeguards the legislation should contain.
KG LEGAL KIELTYKA GLADKOWSKI supports international pharmaceutical, biotechnology and healthcare businesses operating in Poland. For legal assistance with pharmaceutical regulation, reimbursement and market access, contact our team at office@kg-legal.pl.
More
Publication date: November 10, 2026
10 November 2026
From 11 November 2026, telecommunications undertakings in Poland must meet new technical and operational requirements for the interfaces that give law enforcement and security agencies access to communications and related data. Interfaces already running under existing agreements may stay on the previous standard, but for no longer than 36 months. The new rules add 5G standards, real-time delivery and a dedicated interface for retained data.
More